Sarcophix:
EphA2 Targeted Doxorubicin-siRNA PEGylated Nanoliposomes for Osteosarcoma Treatment
Development Stage: In-vivo experiments
Industry: Cancer treatment
Osteosarcoma is one of the most common types of primary malignant bone tumors. The population affected is predominantly children, teenagers, and young adults. OS can be treated with surgery, radiotherapy, and chemotherapy. There is a clear need for newer effective agents especially for patients who are afflicted with metastatic and recurrence tumors.
The major cause of the limited efficacy of current therapies is the development of multidrug resistance (MDR) to cytotoxic therapy, which is thought to occur by the selection of resistant cell clones after a treatment cycle. These resistant clones can then lead to relapse or metastatic disease progression in a later stage of the disease. New treatments, aimed to subvert therapy resistance and reestablish OS sensitivity to existing therapies, are urgently needed. Furthermore, conventional cancer drugs show different side effects because of non-targeted release and high doses requirement.
Sarcophix formulations by implementing different technologies try to solve these challenges.
A series of nano-liposomal drug delivery formulations with different technologies have been used including PEGylation, and siRNA loading, EphA2 targeting to increase our formulation selectivity to cancer cells, reduce side effects, increase blood circulation time, drug loading, etc.Sarcophix™ also used dual drug and gene delivery to overcome MDR.
Key Features
- New liposomal doxorubicin nanoformulation for osteosarcoma treatment
- Increased selectivity toward osteosarcoma cells
- Improved blood circulation time
- Increased toxicity and reduce MDR
- Reducing side effects of free cancer drugs by encapsulation in nanoliposomes
- Nano-liposome production under 100 nanometer in size
- Active targeting of nanoliposomes
- PEGylated nanoliposome production
- Simultaneous drug and gene delivery using nanoliposomes